KOOL - Cesca Therapeutics Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue14,52511,92916,042
Cost of Revenue8,6869,18511,293
Gross Profit5,8392,7444,749
Operating Expenses
Research Development2,4973,2305,939
Selling General and Administrative12,58210,37913,669
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-9,240-10,865-14,859
Income from Continuing Operations
Total Other Income/Expenses Net-9,860-5,85921
Earnings Before Interest and Taxes-19,100-16,724-14,838
Interest Expense10,6681,86414
Income Before Tax-29,768-18,588-14,852
Income Tax Expense-673--
Minority Interest---
Net Income From Continuing Ops-29,095-18,588-14,852
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-29,095-18,588-14,852
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-29,095-18,588-14,852